The Wall Street Journal has dug deep into the numbers at Biogen Idec, raising questions about the real value of the company. Biogen Idec is one of the original pioneers in biotechnology and recently came into play after Carl Icahn (photo) made an overture to buy it. After a bout of enthusiasm, observers now are wondering about the impact of near-term competition for its multiple sclerosis business, the company's shrinking profit share on Rituxan and questions regarding the true value of its pipeline therapies. Nevertheless, a hungry Big Pharma company like Pfizer could easily shrug off any doubters and make a big bid for the company, which is reportedly worth around $23 billion.
- read the article from The Wall Street Journal (sub. req.)
Related Articles:
Biogen Idec in play after Icahn makes his move. Report
Will Big Pharma buy Biogen Idec? Report
Biogen Idec sale could have big impact in Boston. Report
Biotech stocks surge as investors anticipate buyouts. Report